TMS denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on TMS
## Why Humana Denies TMS as Duplicate Therapy
A duplicate-therapy denial from Humana means the plan has determined that TMS is duplicative of another treatment you are already receiving — most commonly, that you are currently undergoing a course of antidepressant medication or psychotherapy that Humana considers to address the same clinical indication. This denial reason is often factually incorrect or based on an incomplete understanding of how TMS works alongside other treatments, and it is a denial category that responds well to clinical clarification.
TMS is frequently used in conjunction with medication and therapy, not as a replacement. The duplicate-therapy rationale collapses when your clinician explains the distinct mechanism, the distinct clinical role, and why concurrent use is medically necessary for your specific case.
## Your Appeal Rights
Under ACA §2719 and ERISA §503, you have the right to a full internal appeal followed by an independent external review if the internal appeal is denied. External review is conducted by an accredited organization with no connection to Humana. You typically have approximately 180 days from receipt of the denial to initiate the internal appeal. Expedited review is available if your clinical situation is urgent.
## What to Gather
- Prescriber explanation letter: A detailed letter from your treating clinician explaining why TMS is not duplicative — specifically, how TMS acts through a different mechanism than the concurrent treatment, what clinical goal TMS addresses that the other treatment does not, and why combined treatment is medically necessary.
- Treatment documentation for each therapy: Records showing the current treatment(s) Humana cited as the basis for duplication, including the diagnosis, duration, and response to date.
- Clinical distinction narrative: Your clinician should address Humana's specific claim — what treatment did they identify as duplicative, and why is that characterization clinically incorrect?
- Diagnosis and severity records: Chart notes and assessment documentation establishing the severity and complexity of your condition.
## Criteria-Mapping Structure
Reframe the appeal around the clinical distinction:
| Humana's Duplicate Claim | Your Clinical Rebuttal | |---|---| | Treatment Humana identified as duplicate | [Name the treatment from the denial letter] | | Why TMS is not duplicative (mechanism) | [Prescriber letter: distinct mechanism of action] | | Why concurrent treatment is necessary | [Clinical rationale: partial response to existing treatment, additive benefit] | | Diagnosis severity supporting both treatments | [Chart documentation] |
Duplicate-therapy denials are among the most reversible when supported by a clear prescriber letter that directly addresses the specific treatment Humana cited.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →